E5103 Cardiac Toxicity Form [Form No. 2608v2] NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder:

  1. 8/26/12 8/26/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
  3. 6/8/15 6/8/15 -
Uploaded on:

June 8, 2015

To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

E5103 Cardiac Toxicity Form NCT00433511

INSTRUCTIONS: Complete this form and submit original to the ECOG Coordinating Center within one week of registration. Keep a copy for your files

ECOG clinical trial administrative data
Patient demographics
Data amendment
On Treatment
On Treatment Report Period (Choose one x)
Off Treatment
Off Treatment Report Period (since registration)
Cardiovascular assessment
Has the patient had a documented assessment of cardiac function (this report period)
Method of Evaluation (LVEF)
Clinical Episode of CHF (requires symptoms associated with a decrease in LVEF to below the institutional LLN - Specify whether any of the following adverse events have occurred during this report period record an answer for each event listed below)
S3 Gallop
Basilar Rales
Dyspnea on exertion, orthopnea or paroxysmal noctural dyspnea
Was dyspnea grade 1 (If yes to Dyspnea:)
Abnormal ECG (<specify>)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial